Dirk Sibbing on OCEANIC-STROKE Demonstrationg Superiority of Asundexian vs. Placebo
Dirk Sibbing, Professor, Cardiologist and Angiologist at Lauterbacher Mill Private Clinic and LMU Munich, shared on LinkedIn:
”Positive late-breaking news on a new pathway – Factor XIa inhibition – for antithrombotic treatment for stroke risk reduction
Secondary prevention trial in patients (>12,000 pts) after non-cardioembolic ischemic stroke or high-risk TIA
OCEANIC-STROKE demonstrates superiority of asundexian vs. Placebo (in both study arms in combo with antiplatelet therapy), showing significant reduction in ischemic stroke risk, without increasing bleeding risk
OCEANIC-STROKE is the first successfully completed Phase III study of a Factor XIa inhibitor (50 mg p.o. once daily)
Adding an antithrombotic agent (here: asundexian) to best medical treatment (here: antiplatelet treatment) with significant reduction in ischemic risk and – at the same time – without (!) increasing overall bleeding risk is highly remarkable!
Uncoupling thrombosis- and haemostasis risk”
Read the full article here.
Stay updated with Hemostasis Today.
-
Sep 10, 2026, 05:12Douglas S. Campbell: Great to See a Strong Japanese Presence in 2026 Lasker Awards
-
Sep 10, 2026, 05:11Jan Hartmann: New Transformative Treatment for Hemophilia A
-
Sep 10, 2026, 05:09Shelby Bradford: Award-Winning Science Incoming
-
Sep 9, 2026, 17:57CRISPR/Cas Gene Editing in β-Thalassemia: From Molecular Correction to Clinical Reality
-
Sep 9, 2026, 17:38Cardiovascular Health in Bleeding Disorders – EHC
-
Sep 9, 2026, 17:33Manasvi Shah: Co-Inheritance of Alpha Globin Gene Multiplication With Beta Globin Gene Abnormalities
-
Sep 9, 2026, 17:29Christina Crossette-Thambiah: One of the Largest Studies to Date in Antiphospholipid Syndrome
-
Sep 9, 2026, 17:25Alan Nurden: A miR-146a Variant Reveals a New Pathway Linking Platelet Metabolism and Thrombosis
-
Sep 9, 2026, 17:17When Is Thrombophilia Testing Appropriate and How Can the Evidence Guide Clinical Care? – ISTH